Rhythm Pharmaceuticals (RYTM)
(Real Time Quote from BATS)
$49.13 USD
+0.04 (0.08%)
Updated Sep 11, 2024 01:42 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Rhythm Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 276 | 333 | 295 | 173 | 292 |
Receivables | 15 | 6 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 9 | 3 | 0 | 0 | 0 |
Other Current Assets | 9 | 12 | 13 | 9 | 10 |
Total Current Assets | 308 | 354 | 308 | 182 | 302 |
Net Property & Equipment | 1 | 2 | 3 | 3 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 7 | 8 | 5 | 0 | 0 |
Deposits & Other Assets | 15 | 17 | 12 | 0 | 0 |
Total Assets | 333 | 382 | 330 | 187 | 309 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 5 | 6 | 5 | 10 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 48 | 33 | 30 | 13 | 14 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 7 | 0 | 0 |
Total Current Liabilities | 55 | 40 | 43 | 18 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 106 | 76 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 163 | 118 | 45 | 21 | 28 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,064 | 974 | 813 | 626 | 606 |
Retained Earnings | -895 | -710 | -529 | -459 | -325 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 170 | 264 | 284 | 167 | 281 |
Total Liabilities & Shareholder's Equity | 333 | 382 | 330 | 187 | 309 |
Total Common Equity | 170 | 264 | 284 | 167 | 281 |
Shares Outstanding | 59.10 | 56.30 | 50.20 | 44.20 | 43.90 |
Book Value Per Share | 2.87 | 4.69 | 5.66 | 3.77 | 6.40 |
Fiscal Year End for Rhythm Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 319 | 201 | 276 | 299 | 254 |
Receivables | 18 | 15 | 15 | 15 | 14 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 12 | 9 | 9 | 8 | 6 |
Other Current Assets | 9 | 11 | 9 | 8 | 10 |
Total Current Assets | 357 | 236 | 308 | 329 | 284 |
Net Property & Equipment | 1 | 1 | 1 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 7 | 7 | 7 | 7 | 7 |
Deposits & Other Assets | 13 | 14 | 15 | 15 | 16 |
Total Assets | 382 | 259 | 333 | 354 | 310 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 8 | 5 | 4 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 48 | 45 | 48 | 44 | 36 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 1 | 1 |
Total Current Liabilities | 55 | 54 | 55 | 50 | 46 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 108 | 107 | 106 | 105 | 79 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 36 | 1 | 1 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 202 | 197 | 163 | 157 | 128 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 140 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,108 | 1,098 | 1,064 | 1,051 | 991 |
Retained Earnings | -1,068 | -1,036 | -895 | -853 | -809 |
Other Equity | -1 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 180 | 62 | 170 | 197 | 182 |
Total Liabilities & Shareholder's Equity | 382 | 259 | 333 | 354 | 310 |
Total Common Equity | 39 | 62 | 170 | 197 | 182 |
Shares Outstanding | 60.90 | 60.90 | 59.10 | 56.90 | 56.90 |
Book Value Per Share | 0.65 | 1.01 | 2.87 | 3.47 | 3.20 |